Claims for Patent: 10,309,966

Summary for Patent: 10,309,966

Title:	Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
Abstract:	The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated cancer. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist.
Inventor(s):	Sibilia; Maria (Vienna, AT)
Assignee:	Medizinische Universitat Wien (Vienna, AT)
Application Number:	15/312,252
Patent Claims:	1. A method of testing a subject for the need of treatment of an inflammation-associated cancer, wherein the subject has or is suspected of having said cancer, and wherein the inflammation-associated cancer is hepatocellular carcinoma or an inflammation-associated intestinal cancer, the method comprising the steps of: (a) obtaining a sample from the subject that comprises a myeloid cell population, wherein the myeloid cells in the myeloid cell population are CD68-positive macrophage cells and/or Kupffer cells and are from within said cancer or from the tissue adjacent to said cancer; (b) testing the myeloid cell population to identify that portion of myeloid cells that detectably express EGFR, wherein greater than 5% of myeloid cells in the myeloid cell population detectably express EGFR; and (c) treating the subject by administering a therapeutically effective amount of an EGFR inhibitor/antagonist to the subject. 2. The method of claim 1, wherein the subject is a human. 3. The method of claim 1, wherein greater than 10% of myeloid cells in the myeloid cell population detectably express EGFR. 4. The method of claim 3, wherein greater than 20% of myeloid cells in the myeloid cell population detectably express EGFR. 5. The method of claim 4, wherein greater than 30% of myeloid cells in the myeloid cell population detectably express EGFR. 6. The method of claim 1, wherein the sample is a cancer tissue biopsy sample. 7. The method of claim 1, wherein the myeloid cells are CD68-positive macrophage cells. 8. The method of claim 1, wherein the inflammation-associated cancer is hepatocellular carcinoma. 9. The method of claim 1, wherein the sample is a liver tissue sample. 10. The method of claim 1, wherein the myeloid cells are Kupffer cells. 11. The method of claim 1, wherein the inflammation-associated cancer is colorectal cancer. 12. The method of claim 11, wherein the sample is a colorectal tissue sample or a colorectal polyp. 13. The method of claim 1, wherein the myeloid cells are identified by determining a level of translation of EGFR therein. 14. The method of claim 13, wherein the level of translation is determined using an immunohistochemical method, an enzyme-linked immunosorbent assay, or a radioimmunoassay. 15. The method of claim 1, wherein the EGFR inhibitor/antagonist is selected from the group consisting of gefitinib, erlotinib, lapatinib, afatinib, neratinib, ABT-414, dacomitinib, AV-412, PD 153035, vandetanib, PKI-166, pelitinib, canertinib, icotinib, poziotinib, BMS-690514, CUDC-101, AP26113, XL647, cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, and a pharmaceutically acceptable salt thereof.

Details for Patent 10,309,966

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2034-05-22
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2034-05-22
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2034-05-22